Immix Biopharma (Nasdaq: IMMX)

Director, Medical Affairs

Immix Biopharma, Inc.

Our 3 Core Values

• Intelligence
• Integrity
• Initiative

We are seeking a savvy strategic and scientific leader to build and lead Medical Affairs at Immix Biopharma at a pivotal moment as we advance our lead asset, NXC-201, toward potential approval in relapsed/refractory AL amyloidosis.

Immix Biopharma is developing NXC-201, a differentiated BCMA-directed CAR-T therapy with Breakthrough Therapy designation, for FDA approval based on a single-arm, registrational Phase 1/2 study. We are moving with urgency – from end of study in 2026 to potential launch in 2027 – to transformative treatment for these patients with significant unmet need.

This is a rare opportunity to build Medical Affairs from the ground up. The Director, Medical Affairs will define the vision, strategy, and execution of a high-impact, scientifically rigorous organization that will shape how our data are understood, how our therapy is used appropriately in clinical practice, and how we engage with the broader medical and scientific community. This role will also be responsible for establishing a strong partnership with Commercial by developing shared strategic imperatives and collaborating on launch readiness.

This role requires more than scientific excellence. It requires a leader who can operate with strategic clarity in the face of uncertainty, influence across functions without direct authority, and translate complex data into a compelling and credible scientific narrative for diverse stakeholders.

What You Will Do

Define and build Medical Affairs

• Establish the vision, strategy, and operating model for ground up Medical Affairs build
• Build and lead a lean, high-performing team aligned to company priorities
• Create a culture grounded in scientific rigor, integrity, and compliance

Shape scientific and clinical narrative

• Develop and articulate a clear, evidence-based scientific narrative for NXC-201, grounded in deep understanding of the data and disease landscape
• Lead scientific exchange with key opinion leaders, investigators, academic institutions and patient advocacy groups
• Oversee publication strategy, congress activity, and data dissemination

Drive integrated evidence and scientific strategy

• Partner with Clinical Development, Biostatistics, Regulatory, and Commercial to define and execute an integrated evidence generation plan beyond the registrational study to address key evidence gaps and strategic priorities
• Serve as a key scientific partner in shaping development strategy, trial design, endpoints, and data interpretation
• Ensure alignment between clinical data, scientific communication, and external stakeholder needs

Engage the external ecosystem

• Build and deploy a field medical organization capable of high-quality, peer-to-peer scientific exchange
• Provide executive leadership, in partnership with Commercial Operations and IT, for the strategy, development, and governance of MSL field enablement capabilities, including CRM platform, medical analytics, leadership dashboards, and MLR review
• Build trusted relationships with KOLs, treatment centers, and patient advocacy groups
• Represent Immix in advisory boards, scientific forums, and external collaborations
• Bring external insights back into the organization to inform strategy and decision-making

Qualifications

Education & Experience

• Advanced degree required (MD, PhD, PharmD, or equivalent preferred)
• 3-5+ years experience in the biopharmaceutical industry with focus in hematology/oncology; experience in plasma cell disorders strongly preferred
• Medical Affairs leadership with demonstrated success building and leading teams
• Familiarity with complex and composite clinical endpoints (MRD, CHR) strongly preferred
• Proven experience supporting or leading a product launch; cell and/or gene therapy launch experience a plus
• Experience in small or emerging biotech environments a plus; experience supporting breakthrough-designated, accelerated approval and/or single-arm registrational programs a plus

Capabilities

• Deep scientific and clinical acumen, with the ability to engage credibly at the highest levels of the medical community
• Strategic mindset with the ability to identify key decisions, frame trade-offs, and guide cross-functional alignment
• Ability to translate complex data into a clear, compelling, and credible scientific narrative
• Demonstrated ability to operate effectively in ambiguous, fast-paced environments
• Strong leadership and team-building capabilities with a commitment to developing others
• Excellent communication skills, with the ability to influence internal and external stakeholders, including experience with C-suite and Board executive leadership

Distinctive Strengths

• Equally comfortable in deep scientific exchange and executive-level strategic dialogue
• Able to translate complex data into a compelling narrative for diverse stakeholders
• High degree of initiative, intellectual curiosity, and ownership
• Collaborative, low-ego leader who can work across functions to achieve shared goals

Location & Travel

• US-based, remote
• Ability to travel approximately 30–50% as required

About Immix Biopharma

Immix Biopharma is committed to harnessing the immune system through innovative cell therapies and other modalities to deliver widely accessible cures. Patients are waiting.

Our lead asset, NXC-201, is a differentiated BCMA-directed CAR-T therapy being developed for relapsed/refractory AL amyloidosis—an area of critical unmet need. We are advancing rapidly toward potential approval and launch, with the goal of bringing a transformative therapy to patients.

• We are guided by three core values: Intelligence, Integrity, and Initiative. We are building a team of thoughtful, driven individuals who are motivated by the opportunity to make a meaningful impact for patients and to help define the future of our company.

Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is the global leader in relapsed/refractory AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that is designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.

This job description reflects the technical, pre-launch, and operational focus of the role and is not intended to be an exhaustive list of responsibilities or qualifications.